

In response, applicant has canceled Claims 1-10, and added new Claims 11-15. Support for new Claims 11-15 is found in canceled Claims 3, 5, and 9. Applicant has included the median particle size of the oxacarbazepine from canceled Claim 9 into new Claim 11.


The Examiner has rejected Claims 1-4, 6, 7, 9 and 10 under 35 U.S.C. 112, second paragraph, as being indefinite.

In response, applicant has removed any indefinite language from new Claims 11-15.

Applicant respectfully request that the Examiner enter applicant's amendment, remove all rejections and pass the application to issuance.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6950

  
\_\_\_\_\_  
John D. Thallemer  
Attorney for Applicant  
Reg. No. 34,940

Date: December 8, 2000